Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications

References

• Abernethy D. R., Greenblatt D. J., Ameer B., Snader R. I. Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. Journal of Pharmacology and Experimental Therapeutics 1985; 234: 345–349
   PubMed Web of Science ®Google Scholar
• Back D. J., Purba H. S., Park B. K., Ward S. A., Orme M. L'E. Effect of chloroquine and primaquine on antipyrine metabolism. British Journal of Pharmacology 1983; 16: 497–502
   Google Scholar
• Back D. J., Tjia J. F., Karbwang J., Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolies. British Journal of Clinical Pharmacology 1988; 26: 23–29
   PubMed Web of Science ®Google Scholar
• Back D. J., Tjia J., Moenig H., Ohnhaus E. E., Park B. K. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. European Journal of Clinical Pharmacology 1988; 34: 157–163
   PubMed Web of Science ®Google Scholar
• Bailey E., Farmer P. B., Shuker D. E. G. Estimation of exposure to alkylating carcinogens by the GC-MS determination of adducts to hemoglobin and nucleic acid bases in urine. Archives of Toxicology 1987; 60: 187–191
   PubMed Web of Science ®Google Scholar
• Birkett D. J., Robson R. A., MacManus M. E., Stupans I., Miners J. O. Enzymic determinants of metabolic drug clearance in man. Toxicological and Immunological Aspects of Drug Metabolism and Environmental Chemicals, R. W. Estabrook, E. Lindenlaub, F. Oesch, A. L. de Weck. F. K. Schattauer, Stuttgart 1987; 261–274
   Google Scholar
• Brown M. W., Maldonaldo A. L., Speeg K. V. Effect of ketoconazole on hepatic oxidative drug metabolism. Clinical Pharmacology and Therapeutics 1985; 37: 290–297
   PubMed Web of Science ®Google Scholar
• Brown C. R., Jacob P., Wilson M., Benowitz N. L. Changes in rate and pattern of caffeine metabolism after cigarette abstinence. Clinical Pharmacology and Therapeutics 1988; 43: 488–491
   PubMed Web of Science ®Google Scholar
• Challiner M., Park B. K., Odum J., Orton T. C. The effect of 3-methylcholanthrene on urinary 6β-hydroxycortisol excretion and hepatic enzyme activity in the maimoset monkey. (Callithrix jacchus). Biochemical Pharmacology 1981; 30: 2131–2134
   PubMedGoogle Scholar
• Choonara I. A., Cholerton S., Haynes B. P., Breckenridge A. M., Park B. K. Stereoselective interaction between the R enantiomer of warfarin and cimetidine. British Journal of Clinical Pharmacology 1986; 21: 271–277
   PubMed Web of Science ®Google Scholar
• Combalbert J., Fabre I., Fabre G., Dalet I., Derancourt J., Cano J. P., Maurel P. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450 IIIA gene subfamily. Drug Metabolism and Disposition 1989; 17: 197–207
   PubMed Web of Science ®Google Scholar
• Danhof M., Verbeek R. M. A., van Boxtel C. J., Boeijinga J. K., Breimer D. D. Differential effects of enzyme induction on antipyrine metabolite formation. British Journal of Clinical Pharmacology 1982; 13: 379–386
   PubMed Web of Science ®Google Scholar
• Distlerath L. M., Reilly P. E. B., Martin M. V., Davis G. G., Wikinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochrome P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1985; 260: 9057–9067
   PubMed Web of Science ®Google Scholar
• Dossing M., Pilsgaard H., Rasmussen B., Enghusen-Poulson H. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. European Journal of Clinical Pharmacology 1983; 25: 215–222
   PubMed Web of Science ®Google Scholar
• Fabre G., Crevat-Pisano P., Dragna S., Covo J., Barray Y., Cano J. P. Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. Biochemical Pharmacology 1988; 37: 1947–1953
   PubMedGoogle Scholar
• Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacological Reviews 1989; 40: 243–288
   Web of Science ®Google Scholar
• Grygiel J. J., Miners J. O., Drew R., Birkett D. J. Differential effects of cimetidine on theophylline metabolic pathways. European Journal of Clinical Pharmacology 1984; 26: 335–340
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Molecular Pharmacology 1988; 33: 500–508
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolff T., Waxman D. J. Characterization of rat and numan liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1986; 261: 5051–5060
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Muller-Enoch D., Blair I. Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology 1986; 30: 287–295
   PubMed Web of Science ®Google Scholar
• Henry D. A., McDonald I. A., Kitchingman G., Bell G. D., Langman M. J. S. Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism. British Medical Journal 1980; 2: 775–777
   Google Scholar
• Hepner G. W., Vessell E. S. Aminopyrine disposition: Studies on breath, saliva and urine of normal subjects and patients with liver disease. Clinical Pharmacology and Therapeutics 1976; 20: 654–660
   PubMedGoogle Scholar
• Heusner J. J., Dukes G. E., Rollins D. E., Tollan K. G., Galinsky R. E. Effect of chronically administered ketoconazole on the elimination of theophylline in man. Drug Intelligence in Clinical Pharmacology 1987; 21: 514–517
   PubMedGoogle Scholar
• Hussey A. J., Hayes J. D., Beckett G. J. The polymorphic expression of neutral glutathione S-transferase in human mononuclear leucocytes as measured by specific radioimmunoassay. Biochemical Pharmacology 1987; 36: 4013–4015
   PubMed Web of Science ®Google Scholar
• Idle J. R., Smith R. L. The debrisoquine hydroxylation gene: a gene of multiple consequence. Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics, L. Lemberger, M. M. Reidenberg. American Society for Pharmacology and Therapeutics, Bethesda, MD 1984; 148–164
   Google Scholar
• Kalow W. Genetic variation in the human hepatic cytochrome P-450 system. European Journal of Clinical Pharmacology 1987; 31: 633–641
   PubMed Web of Science ®Google Scholar
• Kellermann G., Luyten-Kellermann M., Shaw C. R. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. American Journal of Human Genetics 1973; 25: 327–331
   PubMed Web of Science ®Google Scholar
• Kotake A. N., Schoeller D. A., Lambert G. H., Baker A. L., Schaffer D. D., Joseph H. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clinical Pharmacology and Therapeutics 1982; 32: 261–269
   PubMed Web of Science ®Google Scholar
• Landay R. A., Gonzalez M. A., Taylor J. C. Effect of phenobarbital on theophylline disposition. Journal of Allergy and Clinical Immunology 1978; 62: 27–34
   PubMed Web of Science ®Google Scholar
• McLean A. E. M. Is enzyme induction good for you? A problem of epidemiology and toxicology. Human Toxicology 1988; 7: 419–422
   PubMedGoogle Scholar
• Mannervik B., Alin P., Guthenberg C., Jensson H., Tahir M. K., Warholm M., Jornvall H. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proceedings of the National Academy of Sciences, USA 1985; 82: 7202–7206
   PubMed Web of Science ®Google Scholar
• Mertes I., Fleischmann R., Glatt H. R., Oesch F. Interindividual variation in the activities of cytosolic and microsomal epoxide hydrolase in human liver. Carcinogenesis 1985; 6: 219–223
   PubMedGoogle Scholar
• Michnovicz J. J., Herschopf R. J., Naganuma H., Bradlow H. L., Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. New England Journal of Medicine 1986; 315: 1305–1309
   PubMed Web of Science ®Google Scholar
• Miners J. O., Attwood J., Birkett D. J. Determinants of acetaminophen metabolism: Effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. Clinical Pharmacology and Therapeutics 1984; 35: 480–486
   PubMed Web of Science ®Google Scholar
• Moody D. E., Hammock B. D., Ruebner B. H., Hillman D. W., Hillman J. H. Immunochemical comparison of human and rhesus monkey liver microsomal and the hepatocellular carcinoma-induced human serum epoxide hydrolases (preneoplastic antigens): basis for an enzyme-linked immunosorbent assay. Carcinogenesis 1989; 1p.: 343–349
   Google Scholar
• Namkung M. J., Yang H. L., Hulla J. E., Juchau M. R. On the substrate specificity of cytochrome P-450 IIIA1. Molecular Pharmacology 1988; 34: 628–637
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Adesnik M., Coon M. J., Estabrook R. W., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Kemper B., Levin W., Phillips I. R., Sato R., Waterman M. R. The P-450 gene superfamily: recommended nomenclature. DNA 1987; 6: 1–11
   PubMedGoogle Scholar
• Ohnhaus E. E., Breckenridge A. M., Park B. K. Urinary excretion of 6β-hydroxycortisol and the time course of measurement of enzyme induction in man. European Journal of Clinical Pharmacology 1989; 36: 39–46
   PubMed Web of Science ®Google Scholar
• Paigen B., Gurtoo H. L., Minowada J., Houten L., Vincent R., Paigen K., Parker N. B., Ward E., Hayner N. T. Questionable relation of aryl hydrocarbon hydroxylase to lung-cancer risk. New England Journal of Medicine 1977; 297: 346–350
   PubMed Web of Science ®Google Scholar
• Pang K. S., Rowland M., Tozer T. N. In vivo evaluation of Michaelis-Menten constants of hepatic drug-eliminating systems: a commentary. Drug Metabolism and Disposition 1978; 6: 197–200
   PubMed Web of Science ®Google Scholar
• Park B. K. Assessment of urinary 6β-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. British Journal of Clinical Pharmacology 1981; 12: 97–102
   PubMedGoogle Scholar
• Park B. K. Metabolic basis of adverse drug reactions. Journal of the Royal College of Physicians (London) 1986; 20: 195–200
   PubMedGoogle Scholar
• Park B. K., Kitteringham N. R. Relevance of and means of assessing induction and inhibition of drug metabolism in man. Progress in Drug Metabolism, G. G. Gibson. Taylor & Francis, London 1989; Vol. 11: 1–60
   Google Scholar
• Park B. K., Breckenridge A. M. Clinical implications of enzyme induction and enzyme inhibition. Clinical Pharmacokinetics 1981; 36: 39–46
   Google Scholar
• Parke D. V. Activation mechanisms to chemical toxicity. Archives of Toxicology 1987; 60: 5–15
   PubMed Web of Science ®Google Scholar
• Pumford N. R., Hinson J. A., Potter D. W., Rowland K. L., Benson R. W., Roberts D. W. Immunochemical quantitation of 3-(cysteine-S-yl)acetaminophen adducts in serum and liver proteins of acetaminophen-treated mice. Journal of Pharmacology and Experimental Therapeutics 1989; 289: 190–196
   Google Scholar
• Rettie A. E., Eddy A. C., Heimark L. D., Gibaldi M., Trager W. F. Characteristics of warfarin hydroxylation catalysed by human liver microsomes. Drug Metabolism and Disposition 1989; 17: 265–270
   PubMedGoogle Scholar
• Riley R. J., Maggs J. L., Lambert C., Kitteringham N. R., Park B. K. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. British Journal of Clinical Pharmacology 1988; 26: 577–588
   PubMed Web of Science ®Google Scholar
• Robson R. A., Miners J. O., Matthews A. P., Stupans I., Meller D., McManus M. E., Birkett D. J. Characterization of theophylline metabolism by human liver microsomes: inhibition and immunochemical studies. Biochemical Pharmacology 1988; 37: 1651–1659
   PubMed Web of Science ®Google Scholar
• Rowland M. Kinetics of drug-drug interactions,. Pharmacology and Pharmacokinetics, T. Teorell, R. L. Dedrick, P. G. Condliffe. Plenum Press, London 1975; 321–328
   Google Scholar
• Schellens J. H. M., van der Wart J. H. F., Brugman M., Breimer D. D. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine as assessed by a ‘cocktail’ study design. Journal of Pharmacology and Therapeutics 1989; 249: 638–645
   PubMed Web of Science ®Google Scholar
• Scott A. K., Khir A. S. M., Bewsher P. D., Hawksworth G. M. Oxazepam pharmacokinetics in thyroid disease. British Journal of Clinical Pharmacology 1984; 17: 49–54
   PubMed Web of Science ®Google Scholar
• Seidegard J., De Pierre J. W., Pero R. W. Hereditary interindividual differences in the glutathione transferase activity towards trans-stilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s). Carcinogenesis 1985; 6: 1211–1216
   PubMed Web of Science ®Google Scholar
• Seidegard J., Guthenberg C., Pero R. W., Mannervik B. The trans-stilbene oxide-active glutathione transferase in human mononuclear leukocytes is identical with the hepatic glutathione transferase μ. Biochemical Journal 1987; 246: 783–785
   PubMed Web of Science ®Google Scholar
• Seideman P., Ericsson O., Groningsson K., von Bahr C. Effect of pentobarbital on the formation of diastereomeric oxazepam glucuronides in man: analysis by high performance liquid chromatography. Acta Pharmacologica et Toxicologica 1981; 49: 200–204
   PubMedGoogle Scholar
• Serlin M. J., Sibeon R. G., Mossman S., Breckenridge A. M., Williams J. B. B., Atwood J. L., Willoughby J. M. T. Cimetidine: interaction with oral anticoagulants in man. Lancet 1979; ii: 317–320
   Google Scholar
• Sesardic D., Davis D. S., Edwards R. J., Boobis A. R. Identification of the major isozyme of cytochrome P-450 induced by cigarette smoking in man. Enzyme Induction in Man, E. A. Sotaniemi, R. O. Pelkonen. Taylor & Francis, London 1987; 33–46
   Google Scholar
• Shaw P. N., Houston J. B., Rowland M., Hopkins K., Thiercelin J. F., Morselli P. L. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. British Journal of Clinical Pharmacology 1985; 20: 611–618
   PubMed Web of Science ®Google Scholar
• Siest G., Batt A. M., Fournel-Gigleux S., Galteau M. M., Wellman-Bednawska M., Minn A., Amar Costesec A. Induction of plasma and tissue enzymes by drugs: significance in toxicological studies. Xenobiotica 1988; 18: 21–34
   PubMed Web of Science ®Google Scholar
• Sonino N. The use of ketoconazole as an inhibitor of steroid production. New England Journal of Medicine 1987; 317: 812–818
   PubMed Web of Science ®Google Scholar
• Spielberg S. P. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. Federation Proceedings 1984; 43: 2308–2313
   PubMedGoogle Scholar
• Staiger Ch., Schlicht F., Walter E., Gundert-Remy U., Hildebrandt R., de Vries J., Wang N. S., Harenberg J., Weber E. Effect of single and multiple doses of sulphipyrazone on antipyrine metabolism and urinary excretion of 6-β hydroxycortisol. European Journal of Clinical Pharmacology 1983; 25: 797–801
   PubMed Web of Science ®Google Scholar
• Stommel P., Mueller G., Stuecker W., Verkoyen C., Schoebel S., Norpoth K. Determination of S-phenylmercapturic acid in the urine—an improvement in the biological monitoring of benzene exposure. Carcinogenesis 1989; 10: 279–282
   PubMed Web of Science ®Google Scholar
• Syvalahti E. K. G., Pihlajamaki K. K., Lisalo E. J. Rifampicin and drug metabolism. Lancet 1974; ii: 232–233
   Google Scholar
• Teunissen M. W. E., Kleinbloesem C. H., de Leede L. G. J., Breimer D. D. Influence of cimetidine on steady state concentrations and metabolite formation from antipyrine infused with a rectal osmotic mini pump. European Journal of Clinical Pharmacology 1985; 28: 681–687
   PubMedGoogle Scholar
• Thomas R. C., Ikeda C. J. The metabolic fate of tolbutamide in man and in the rat. Journal of Medicinal Chemistry 1966; 9: 507–510
   PubMed Web of Science ®Google Scholar
• Tingle M. D., Park B. K. Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites. British Journal of Clinical Pharmacology 1990; 29: 549–556
   PubMed Web of Science ®Google Scholar
• Toon S., Low L. K., Gibaldi M., Trager W. F., O'Reilly R. A., Motley C. H., Goulart D. A. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clinical Pharmacology and Therapeutics 1986; 39: 15–24
   PubMed Web of Science ®Google Scholar
• Toverud E-L., Boobis A. R., Brodie M. J., Murray S., Bennett P. N., Whitmarsh P. N., Davies D. S. Differential induction of antipyrine metabolism by rifampicin. European Journal of Clinical Pharmacology 1981; 21: 155–160
   PubMed Web of Science ®Google Scholar
• Vessell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clinical Pharmacology and Therapeutics 1979; 26: 275–286
   PubMed Web of Science ®Google Scholar
• Vestal R. E., Cusack B. J., Mercer G. D., Dawson G. W., Park B. K. Aging and drug interactions. I. Effect of cimetidine and smoking on the oxidation of theophylline and cortisol in healthy men. Journal of Pharmacology and Therapeutics 1987; 241: 488–500
   PubMed Web of Science ®Google Scholar
• Watkins P. B., Wrighton S. A., Maurei P., Schuetz E. G., Mendez-Picon G., Parker G. A., Guzelian P. S. Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences, USA 1985; 82: 6310–6317
   PubMed Web of Science ®Google Scholar
• Wietholz H., Voegelin M., Arnaud M-J., Bircher J., Presig R. Assessment of the cytochrome P-448 dependent enzyme system by a caffeine breath test. European Journal of Clinical Pharmacology 1981; 21: 53–59
   PubMedGoogle Scholar
• Wietholz H., Zysset Th., Krieten K., Kohl D., Büchsel R., Matern S. Effect of phenytoin, carbamazepine and valproic acid on caffeine metabolism. European Journal of Clinical Pharmacology 1989; 36: 401–406
   PubMedGoogle Scholar
• Zürcher R. M., Frey B. M., Frey F. J. Impact of ketoconazole on the metabolism of prednisolone. Clinical Pharmacology and Therapeutics 1989; 45: 366–372
   PubMed Web of Science ®Google Scholar